{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:18:25Z","timestamp":1770967105396,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,2,8]],"date-time":"2015-02-08T00:00:00Z","timestamp":1423353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The renal status of patients with bone metastases secondary to solid tumors and their treatment with nephrotoxic agents is not well characterized. This retrospective study analyzed electronic medical records data from <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\u2010based oncology clinics to identify adult (age \u226518) solid tumor patients with first bone metastasis diagnosis and \u22651 serum creatinine recorded between January 1, 2009 and December 31, 2013. Patients with multiple myeloma, multiple primary tumor types, acute renal failure, and\/or end\u2010stage renal disease were excluded. Using the Chronic Kidney Disease Epidemiology Collaboration formula, we determined the prevalence of renal impairment (<jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content>: single estimated glomerular filtration rate [<jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content>] value &lt;60\u00a0mL\/min per 1.73\u00a0m<jats:sup>2<\/jats:sup>) and chronic kidney disease (<jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content>: \u22652 <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> values &lt;60, at least 90\u00a0days apart). We also examined the use of intravenous bisphosphonates (<jats:styled-content style=\"fixed-case\">IV BP<\/jats:styled-content>) and other nephrotoxic agents. Approximately half of the 11,809 patients were female. Breast (34%) and lung (28%) tumors were the most common. At bone metastasis diagnosis, mean age was 67\u00a0years and 24% of patients exhibited <jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content>. The 5\u2010year prevalence was 43% for <jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content> and 71% for <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> among <jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content> patients. Nearly half (46%) of <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> patients received <jats:styled-content style=\"fixed-case\">IV BP<\/jats:styled-content> in the 12\u00a0months following their confirming <jats:styled-content style=\"fixed-case\">eGFR<\/jats:styled-content> and 13% of these patients received at least one other nephrotoxic agent during that period. This is the first <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content>\u2010based study to examine the prevalence of <jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content> among patients with bone metastases from solid tumors. <jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content> is common at bone metastases diagnosis, and a substantial proportion of patients develop <jats:styled-content style=\"fixed-case\">RI<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">CKD<\/jats:styled-content> as their disease progresses. Whenever possible, treatments that are potentially less damaging for the kidney should be considered for patients with or predisposed to RI.<\/jats:p>","DOI":"10.1002\/cam4.403","type":"journal-article","created":{"date-parts":[[2015,2,8]],"date-time":"2015-02-08T05:25:38Z","timestamp":1423373138000},"page":"713-720","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States"],"prefix":"10.1002","volume":"4","author":[{"given":"Jorge","family":"Arellano","sequence":"first","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini K.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally W.","family":"Wade","sequence":"additional","affiliation":[{"name":"Wade Outcomes Research and Consulting Salt Lake City Utah"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Chen","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Pirolli","sequence":"additional","affiliation":[{"name":"IMS Health Plymouth Meeting Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Quach","sequence":"additional","affiliation":[{"name":"IMS Health Plymouth Meeting Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Quigley","sequence":"additional","affiliation":[{"name":"IMS Health Plymouth Meeting Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Liede","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks and South San Francisco California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahakn B.","family":"Shahinian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kidney Epidemiology and Cost Center University of Michigan Ann Arbor Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,2,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2012070690"},{"key":"e_1_2_7_3_1","unstructured":"C\u2010KIN\/Cancer & the Kidney International Network. Available athttp:\/\/www.c-kin.org\/about-c-kin\/(accessed 17 November 2014)."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2010.09.005"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009121210"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.05.030"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041031"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.39"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009010025"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00470111"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.20.2212"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000212381"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.443"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs052"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004383"},{"key":"e_1_2_7_17_1","unstructured":"Highlights of prescribing information for zoledronic acid (Zometa). Available athttp:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/Zometa.pdf(accessed 5 May 2014)."},{"key":"e_1_2_7_18_1","unstructured":"Prescribing information for pamidronate disodium (Aredia). Available athttp:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/aredia.pdf(accessed 5 May 2014)."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.01.018"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22904"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm011"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2009.n.029"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-008-9123-5"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0131-1"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605979"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2011.05.001"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm055"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6583"},{"key":"e_1_2_7_30_1","unstructured":"Oncologic drugs advisory committee meeting. Available athttp:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/questions\/2005-4095Q2_02_Zometa-Aredia-Questions.pdf(accessed 21 May 2014)."},{"key":"e_1_2_7_31_1","unstructured":"Prescribing information for denosumab. Available athttp:\/\/www.xgeva.com\/xgeva-mechanism-of-action.html(accessed 21 May 2014)."},{"key":"e_1_2_7_32_1","unstructured":"FDA approves Xgeva to help prevent cancer\u2010related bone injury.2010. Available athttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm234346.htm(accessed 21 May 2014)."},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.403","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T06:18:29Z","timestamp":1696573109000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,8]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/cam4.403"],"URL":"https:\/\/doi.org\/10.1002\/cam4.403","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,8]]},"assertion":[{"value":"2014-10-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}